Categories: News

Jaguar Health Issues Regulatory Update Regarding Potential Follow-on Indication for Mytesi

SAN FRANCISCO, CA / ACCESSWIRE / March 28, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company is scheduled to meet with the U.S. Food & Drug Administration today, March 28, 2019, to discuss Jagaur’s anticipated protocol for the Company’s planned trial to evaluate Mytesi® (crofelemer) for the symptomatic relief of diarrhea related to anticancer drug therapy.

A significant proportion of patients undergoing cancer treatment experience diarrhea. Novel targeted cancer therapy (TCT) agents, such as epidermal growth factor receptor antibodies and tyrosine kinase inhibitors, with or without standard chemotherapy agents, may activate natural chloride secretion pathways in the gastrointestinal mucosa, potentially leading to secretory diarrhea.

About Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.

About Mytesi®

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the expectation that the Company will conduct a trial to evaluate Mytesi (crofelemer) for treatment of diarrhea related to TCT. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View source version on accesswire.com:
https://www.accesswire.com/540101/Jaguar-Health-Issues-Regulatory-Update-Regarding-Potential-Follow-on-Indication-for-Mytesi

user

Recent Posts

Statement from Minister Champagne and Minister Holland on strengthening Canada’s research support system

OTTAWA, ON, June 17, 2024 /CNW/ - Today, the Honourable François-Philippe Champagne, Minister of Innovation,…

2 hours ago

Parachute Health Launches Integrated Solution of DME Ordering with Prior Authorization

Newly Embedded Prior Authorizations in the Parachute Platform Reduce Costs and Streamlines Administration for Health Plans,…

2 hours ago

T1D Exchange Announces 21 Real-World Data Presentations at the American Diabetes Association (ADA) 84th Scientific Sessions

-       Company invited to speak during three symposia on the impact of quality improvement, the…

2 hours ago

Dental 3D Printing Materials Market to be Worth $5.4 Billion by 2031 – Exclusive Report by Meticulous Research®

REDDING, Calif., June 17, 2024 /PRNewswire/ -- According to a new market research report, 'Dental 3D…

2 hours ago

Renowned Public Health Expert Prof. Siegal Sadetzki Joins Briya

TEL AVIV, Israel, June 17, 2024 /PRNewswire/ -- Briya, a leading medical data retrieval network,…

2 hours ago

VUNO PRESENTS CUTTING-EDGE AI BRAIN TECHNOLOGY AT AAIC – ANALYZING MRI SCANS IN <1 MINUTE TO SUPPORT DIAGNOSIS OF ALZHEIMER'S DISEASE

Potential partners are invited to explore collaboration opportunities with VUNO Med®-DeepBrain®, a highly accurate AI…

2 hours ago